A new deal between a renowned University of Louisville scientist and global pharmaceutical giant Novartis promises to speed up and boost cutting-edge research aimed at helping transplant patients live without anti-rejection drugs.
http://www.courier-journal.com/needlogin?type=login&redirecturl=http%3A%2F%2Fwww.courier-journal.com%2Fapps%2Fpbcs.dll%2Farticle%3FAID%3D2013310300103%26nclick_check%3D1
http://www.courier-journal.com/needlogin?type=login&redirecturl=http%3A%2F%2Fwww.courier-journal.com%2Fapps%2Fpbcs.dll%2Farticle%3FAID%3D2013310300103%26nclick_check%3D1
No comments:
Post a Comment